A股港股医药表现不同，原因是啥？｜第432期精品课程

Core Viewpoint - The pharmaceutical industry is divided into three main sub-sectors: healthcare, biotechnology, and innovative drugs, with varying performance in the current market cycle [5][6][7][51]. Sub-sector Summaries Healthcare - Comprises medical services and medical devices, with a significant number of funds invested in this area [5]. - Examples include eye and dental hospitals for services and devices like pacemakers and syringes [5]. Biotechnology - Focuses on companies in gene diagnostics, biopharmaceuticals, blood products, and human biotechnology, including vaccines [6]. - This index has shown good long-term returns, comparable to healthcare [6]. Innovative Drugs - Primarily related to pharmaceutical manufacturing, with many companies involved in both biotechnology and innovative drugs [7]. Market Performance - Over the past 20 years, the A-share pharmaceutical industry has experienced five cycles of bull and bear markets, with the current cycle from 2019 to 2024 showing a 25% increase in the index as of February 2026 [12][13]. - The Hong Kong pharmaceutical sector has outperformed the A-share market, attributed to differences in fundamentals and valuations [21][51]. Economic Cycles - The current economic cycle for Hong Kong pharmaceuticals is characterized as a boom, with significant profit growth leading to increased valuations [27]. - In contrast, the A-share pharmaceutical sector is in a recovery phase, with modest profit growth [36]. Investment Considerations - Investing in the pharmaceutical sector should focus on undervalued opportunities, ideally purchasing during low valuation periods and holding until high valuation [45][46]. - The volatility of individual industry or thematic investments suggests limiting exposure to 15%-20% of the portfolio for stability [50].